Endothelins and their receptors in cancer: Identification of therapeutic targets

Endothelins and their receptors are important in normal physiology, but have been implicated in various pathophysiological conditions. Members of the so-called “endothelin axis” are dysregulated in a wide range of human cancers, opening the door for novel anticancer therapies. Established cancer chemotherapeutic agents and drugs that target specific components of the endothelin axis have been combined with promising results, but more work is needed in this area. The endothelin axis affects numerous signaling pathways, including Ras, mitogen activated protein kinases, β-catenin/T-cell factor/lymphoid enhancer factor, nuclear factor-κB (NFκB), SNAIL, and mammalian target of rapamycin (mTOR). There is much still to learn about optimizing drug specificity in this area, while minimizing off-target effects. Selective agonists and antagonists of endothelins, their receptors, and upstream processing enzymes, as well as knockdown strategies in vitro, are providing valuable leads for testing in the clinical setting. The endothelin axis continues to be an attractive avenue of scientific endeavor, both in the cancer arena and in other important health-related disciplines.

Graphical abstractEndothelins, their receptors, and upstream processing enzymes have been targeted by anticancer agents (drugs, phytochemicals). Signaling pathways dysregulated in cancer are altered via modulation of the endothelin axis, resulting in changes in gene expression and cancer cell phenotype.Figure optionsDownload full-size imageDownload as PowerPoint slide